Please provide your email address to receive an email when new articles are posted on . In a multicenter, open-label trial, researchers investigated the outcomes of discontinued infliximab use in ...

Infliximab injectable solution is available as brand-name drugs. It’s not available in a generic version. Brand names: Remicade, Inflectra, Renflexis. Infliximab comes in an injectable solution for ...

Intensified or accelerated dosing regimens with infliximab (Remicade) did not improve outcomes compared with the standard regimen in patients with steroid-refractory acute severe ulcerative colitis ...

Aggressive infliximab dosing regimens – intensified induction or accelerated induction – show similar clinical responses and remission rates as the standard infliximab dosing approach in patients with ...

ORLANDO – Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, a researcher ...

Physician and patient resistance to switching from an innovator or reference product to a biosimilar—or from one biosimilar to another—constitutes one of the major barriers to biosimilar adoption, ...

Both infliximab and adalimumab are safe and effective in achieving remission in patients with severe mucocutaneous Behçet syndrome, with adalimumab demonstrating a quicker response time; both drugs ...

Credit: Celltrion USA. Zymfentra is a subcutaneous formulation of Inflectra, a biosimilar to Remicade. Zymfentra is indicated as maintenance treatment only; all patients must complete an IV induction ...

Infliximab biosimilars created price competition causing insurance claims costs for infliximab originator and infliximab biosimilars to decrease, generating significant savings to the health care ...

As Remdantry uses the same Drug Identification Number (DIN) as Inflectra ®, the formulation, indications and dosages of Remdantry will remain the same as that of Inflectra, which was originally ...

TORONTO--(BUSINESS WIRE)--Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new brand name Remdantry TM ...